Lumos Pharma, Inc. announced that it expects to receive $7.5 million in funding from Santé Ventures, LLC and other investors.
January 23, 2014
Share
Lumos Pharma, Inc. announced that it will receive $7,500,000 in equity funding on January 24, 2014. The minimum investment accepted from any outside investor is $45,000. The company will issue securities pursuant to exemption provided under Regulation D.
On the same date, the company received $6,000,000 in its series A from new investor Santé Health Ventures II, L.P., managed by Santé Ventures, LLC.
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.
LUMOS PHARMA, INC. 
